Lotus Pharma

Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results

 

BEIJING, Aug. 16 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals,  Inc.  (BULLETIN BOARD: LTUS)  ("Lotus" or the "Company"), a growing  developer, manufacturer and seller of medicine and drugs in the People's  Republic of China (the "PRC"), reported today its financial results for  the quarter and six months ended June 30, 2010.

Second Quarter ("Q2") 2010 Highlights and Developments:    -- Q2 diluted EPS of $0.12 vs. $0.10 for Q2 2009    -- Q2 net income increased 32% from Q2 2009 to $6.3 million    -- Q2 gross margin of 52.3% compared to 57.9% in Q2 of 2009

 

Für den kompletten Artikel bei "Finanznachrichten.de" und Zahlen diesen Link klicken

http://www.finanznachrichten.de/nachrichten-2010-08/17705171-lotus-pharmaceuticals-reports-strong-second-quarter-2010-financial-results-008.htm

 

Lotus Pharmaceuticals Enter R-Bambuterol(R) Clinical Trial

Neue Tablette wird getestet , soll in 6 Monaten fertiggestellt werden...Kompletter Artikel bei "finanznachrichten.de" unter

http://www.finanznachrichten.de/nachrichten-2010-08/17799189-lotus-pharmaceuticals-enter-r-bambuterol-r-clinical-trial-i-008.htm

...it has entered R-Bambuterol(R) Clinical Trial I on-schedule and is  on-track to complete in six months.  The studies will evaluate the  safety and tolerability of the new drug as well as the biological  activity by measuring responses in healthy volunteers.

The studies are co-monitored by the Company and Beijing Zenith  International Medical Science and Technology Development Company  Limited, a mid-size full-service clinical research organization, and  carried out in Peking University Third Hospital, a top-ranked AAA  hospital recognized as a base adherence to the principles of good  clinical practices (GCPs).

R-Bambuterol(R) Hydrochloride Tablets showed significant efficacy  and less toxicity in preclinical trials as an anti-asthma drug than  Bambuterol currently available in the market.

If it reaches the market, R-Bambuterol(R) Hydrochloride Tablets  would address the Chinese asthma and chronic obstructive pulmonary  disease (COPD) market led by AstraZeneca with a 26 percent share in  2009, according to IMS.

 

http://.../rbambuterol_clinical_trial_i_on_track_lotus_pharma_100830/

R-Bambuterol clinical trial I on track: Lotus Pharma

           

Published:                 30-Aug-2010

                                                                       

Lotus Pharmaceuticals has reached R-Bambuterol clinical  trial I as per the schedule and is on track to complete in six months.

           

In the trials, Lotus is expected to investigate the  safety and tolerability and biological activity of R-Bambuterol by  measuring responses in healthy volunteers.

Previously, in  preclinical trials, R-Bambuterol Hydrochloride tablets demonstrated  efficacy and less toxicity as an anti-asthma drug than Bambuterol  currently available in the market.

R-Bambuterol clinical trials  are co-monitored by Lotus and Beijing Zenith International Medical  Science Technology Development Company Limited.

Lotus is a  developer and producer of drugs and a licensed national seller of  pharmaceutical items in the People's Republic of China (PRC).

 

Congress should investigate China for US investment losses
If most of these small cap Chinese companies start turning into scams or frauds, then that represents more than an SEC issue. That would represent an orchestrated transfer of billions of dollars from the US to China. At some point congress needs to get involved in investigating the situation with these small cap Chinese companies, because China is effectively stealing vast sums of wealth from US citizens.

http://messages.finance.yahoo.com/...amp;mid=6672&tof=4&frt=2